IGF-1 DES

Growth Factor (IGF/MGF)Research Use Only

Also known as: IGF-1 DES(1-3), DES(1-3) IGF-1

IGF-1 DES is a truncated analog of insulin-like growth factor 1 missing the first three N-terminal amino acids, a modification commonly referenced in research literature as increasing potency at the IGF-1 receptor while reducing binding-protein affinity. It is characterized by a comparatively short duration of action. This entry is educational and research-use-only and is not medical advice.

Typical range (research)

Commonly referenced in literature around 50–150 mcg per day (research reference only)

Half-life

~20–30 minutes (short-acting)

Route

Subcutaneous or intramuscular (research)

Common use

Studied as a short-acting, high-potency IGF-1 analog in localized growth-signaling research

Common vial sizes

1 mg

Storage

Lyophilized powder stored frozen or refrigerated away from light; reconstituted solution refrigerated (2–8 °C) and used within a few weeks

Stacking notes

Sometimes discussed alongside IGF-1 LR3 or growth-hormone secretagogues in research contexts

Reported side effects

Hypoglycemia-type symptoms cited in studiesInjection-site reactionLightheadedness reported anecdotally

Regulatory note: Not an approved therapeutic; prohibited in competitive sport under WADA; sold for research purposes only

Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.